Personalisation of therapy for people with type 2 diabetes and cardiovascular disease risk
Feb 14, 2024 - 00:11:56
Radio and PodcastLive Radio & PodcastsHealth
Publication special: Data from the SURPASS program With Prof Carol Wysham
The SURPASS program of phase 3 clinical trials led to the 2022 FDA approval and positive CHMP opinion of the first GIP/GLP-1 receptor agonist, tirzepatide. Join Prof Carol Wysham for an examination of the clinical data f...
Related Episodes
Continue listening to more episodes from Diabetes Knowledge into Practice Podcast.
Effective strategies for encouraging behaviour change
Feb 14, 2024 - 00:14:28
World Diabetes Day – Overcoming Cultural Obstacles to Personalise Diabetes Care
Dec 19, 2023 - 00:13:24
Congress special: Highlights from EASD 2023
Dec 11, 2023 - 00:14:00
Striving for Balance: Achieving Glycemic, Weight, and Cardiorenal Targets in T2D Care
Sep 28, 2023 - 00:12:06
Highlights from ADA 2023
Sep 12, 2023 - 00:19:45
Conference special: EASD 2022 Highlights With Prof. Apostolos Tsapas
Nov 14, 2022 - 00:18:25
Tailoring GLP-1 RA dosing regimens With Dr Harpreet Bajaj
Sep 12, 2022 - 00:14:05